Based on a request from the Food and Drug Administration (FDA), Somaxon Pharmaceuticals, San Diego, is updating information regarding the preclinical testing of SILENOR™, a drug candidate for the treatment of insomnia.
Read MoreAn article reported in Japan’s Corporate News (JCN) lays out the results of a Tokiwa Pharmaceutical survey on sleep and lifestyle.
Read MoreFindings from a recently conducted Bank of America survey, show that Respironics Inc, Murrysville, Pa, is geared up to assume leadership in the sleep therapeutic market, the Associated Press reports.
Read MoreA new study of AMBIEN CR, a controlled-release formula prescription sleep medication approved by the Food and Drug Administration (FDA) for sleep maintenance and sleep induction, found that the drug demonstrated significant improvements in total sleep time (TST), sleep onset latency (SOL), wake time after sleep onset (WASO), sleep quality, and number of awakenings versus placebo.
Read MorePhysicians who treat insomnia may soon find their patients asking for a new medication. After a year of marketing the insomnia medication Rozerem to physicians, the drug maker Takeda Pharmaceuticals North America, Lincolnshire, Ill, is taking its message direct to consumers with an advertising campaign launching today.
Read More